CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its ...
Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif.--(BUSINESS WIRE)-- ...
5-year Agreement Strengthens Cerus’ Leadership Position in the U.S. Market and Will Expand Patient Access to INTERCEPT Platelets Supplying about 40 percent of the nation’s blood supply, the Red Cross ...
Platelet activation is now recognised as a central element in the orchestration of immune and inflammatory processes beyond its classical role in haemostasis and thrombosis. Upon vascular injury or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results